A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL

Trial Profile

A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 26 Sep 2015 Results published in the Vaccine.
    • 04 Feb 2014 According to ClinicalTrials.gov record, the study protocol has been modified into a base study and an extension study.
    • 04 Feb 2014 Planned End Date changed from 1 Nov 2011 to 1 Mar 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top